Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 71610-955

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 71610-955). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0955 19)

Label for Sacubitril and Valsartan 97 mg/103 mg film-coated tablets. Package contains 3060 tablets. Manufactured by MSN Pharmaceuticals Inc., Piscataway, NJ, and repackaged by Aphena Pharma Solutions in Cookeville, TN. Includes storage instructions, barcodes, and prescription-only designation.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Figure-1 (Sacubitril Valsartan Figure 1)

A chart showing the geometric mean ratio and 90% confidence intervals for coadministered drugs relative to reference, plotting changes in AUC and Cmax for various drugs including Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil. The x-axis represents change relative to reference on a scale from 0.5 to 2.*

FDA Label Image

Figure-2 (Sacubitril Valsartan Figure 2)

A chart showing the geometric mean ratio and 90% confidence interval for AUC and Cmax of two substances labeled LBQ657 and Valsartan across different population descriptions, including varying degrees of renal and hepatic impairment, age groups, sex, and race. The chart compares changes relative to reference values using a horizontal axis for change magnitude.*

FDA Label Image

Sacubitril-valsartan-figure-3.jpg (Sacubitril Valsartan Figure 3)

Three Kaplan-Meier survival curves compare Sacubitril and Valsartan versus Enalapril in the PARADIGM-HF study. Figures show time to first occurrence of cardiovascular death or heart failure hospitalization (Figure A), time to cardiovascular death (Figure B), and time to first heart failure hospitalization (Figure C). Each graph plots cumulative failure rate (%) over time since randomization (days) with numbers at risk provided for both treatments at multiple time points.*

FDA Label Image

Structure (Sacubitril Valsartan Structure)

Chemical structure diagram of the active ingredients Sacubitril and Valsartan shown as molecular formulas with bonds and atomic symbols, including sodium ions (Na+).*

FDA Label Image

Sacubitril-valsartanl-figure-4.jpg (Sacubitril Valsartanl Figure 4)

A forest plot chart comparing the hazard ratios of Sacubitril and Valsartan versus Enalapril across various patient subgroups such as age, gender, weight, race, region, NYHA class, kidney function, diabetes status, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension, prior medication use, hospitalization for heart failure, time since diagnosis, cause of heart failure, and ICD use. The chart visualizes relative risk with confidence intervals for each subgroup.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.